At Innocan, we are revolutionizing chronic pain management with our breakthrough LPT-CBD injection, offering a safe and effective alternative to traditional treatments.

Addressing a Real Clinical Need

Chronic pain affects nearly 1 in 5 adults in the U.S. and Europe, significantly impacting their quality of life. Traditional treatments have contributed to adverse consequences, including the opioid epidemic, with over 75% of drug overdose deaths in the U.S attributed to opioids. This crisis highlights the urgent need for safer, more effective pain management solutions.

Innovative LPT-CBD

Our unique LPT-CBD injectable drug provides sustained-release of synthetic CBD with the following key advantages:

• High Bioavailability: Nearly 100% CBD bioavailability ensures maximum therapeutic effect.
• Prolonged Efficacy: A single injection offers continuous relief that can be equivalent to administering oral CBD twice a day for up to 4 weeks
• Safety: Avoids the risks associated with opioid treatments and traditional chronic pain management.
• Synthetic CBD: It is the active pharmaceutical ingredient (API). The CBD is produced synthetically to ensure controlled, purified, and reproducible API production.

Market Impact

The global pain management market is projected to reach $109 billion by 2032, with chronic pain accounting for 58% of this market. Our LPT-CBD injection aims to capture a significant share by addressing the unmet needs of millions suffering from chronic pain.

Pre-Clinical Successes

LPT-CBD has shown promising results in preclinical and observational studies conducted on various animal models:

• Goats: Presented long CBD exposure for 4 weeks and provided significant pain relief resulting from neurological defects and scoliosis while enhancing overall well-being
• Donkey: Provided immediate pain relief and improved mobility for an amputee suffering from Laminitis
• Mini Pigs: Presented long CBD exposure for 28 days and demonstrated excellent drug tolerance with no adverse events
• Rabbits: Supported prolonged CBD exposure from a single injection

Regulatory Progress

We are advancing through the FDA review process and have received positive feedback from the FDA following a pre-IND Type B meeting, with the agency supporting LPT-CBD’s submission under the 505(b)(2) pathway. This regulatory path can accelerate approval, leveraging existing data to facilitate a quicker route to commercialization.

Commitment to Advancing Human Health

We are dedicated to improving human health through scientific innovation. LPT-CBD addresses real clinical needs, enhancing the lives of those suffering from chronic pain.

Discover how Innocan is setting new standards in pain management with our groundbreaking LPT-CBD injection.